SHR-1701 in Subjects With Metastatic or Locally Advanced Solid Tumors
Status:
Recruiting
Trial end date:
2022-01-01
Target enrollment:
Participant gender:
Summary
The main purpose of this study is to assess the safety and tolerability of SHR-1701 at
different dose levels. Study consists of dose-escalation part and an expansion part in
subjects with metastatic or locally advanced solid tumors.